Stifel Financial’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-29,002
| Closed | -$98K | – | 2896 |
|
|
2018
Q3 | $98K | Sell |
29,002
-518
| -2% | -$1.87K | ﹤0.01% | 2671 |
|
|
2018
Q2 | $110K | Sell |
29,520
-3,311
| -10% | -$16.1K | ﹤0.01% | 2624 |
|
|
2018
Q1 | $134K | Buy |
32,831
+300
| +0.9% | +$1.4K | ﹤0.01% | 2538 |
|
|
2017
Q4 | $151K | Buy |
32,531
+1,784
| +6% | +$9.83K | ﹤0.01% | 2498 |
|
|
2017
Q3 | $218K | Sell |
30,747
-5,700
| -16% | -$41K | ﹤0.01% | 2326 |
|
|
2017
Q2 | $263K | Buy |
36,447
+2,711
| +8% | +$16.9K | ﹤0.01% | 2197 |
|
|
2017
Q1 | $207K | Buy |
33,736
+3,478
| +11% | +$19.1K | ﹤0.01% | 2306 |
|
|
2016
Q4 | $178K | Buy |
+30,258
| New | +$165K | ﹤0.01% | 2285 |
|
|
2016
Q3 | – | Sell |
-25,501
| Closed | -$170K | – | 2564 |
|
|
2016
Q2 | $170K | Buy |
+25,501
| New | +$143K | ﹤0.01% | 2298 |
|
|
2016
Q1 | – | Sell |
-10,114
| Closed | -$51K | – | 2440 |
|
|
2015
Q4 | $51K | Sell |
10,114
-10,751
| -52% | -$51.1K | ﹤0.01% | 2279 |
|
|
2015
Q3 | $74K | Sell |
20,865
-29,162
| -58% | -$195K | ﹤0.01% | 2163 |
|
|
2015
Q2 | $499K | Buy |
50,027
+15,323
| +44% | +$164K | ﹤0.01% | 1689 |
|
|
2015
Q1 | $443K | Buy |
34,704
+3,957
| +13% | +$50.9K | ﹤0.01% | 1680 |
|
|
2014
Q4 | $435K | Buy |
30,747
+11,401
| +59% | +$177K | ﹤0.01% | 1688 |
|
|
2014
Q3 | $266K | Sell |
19,346
-772,636
| -98% | -$11.8M | ﹤0.01% | 1854 |
|
|
2014
Q2 | $12.2M | Sell |
791,982
-163,125
| -17% | -$2.31M | 0.11% | 249 |
|
|
2014
Q1 | $16.3M | Buy |
+955,107
| New | +$14.4M | 0.16% | 169 |
|
Stifel Financial's KERX Position: Q4 2018 in Review
Stifel Financial sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 29,002 shares — an estimated $98K sold.
Stifel Financial first reported a position in KERX in Q1 2014 and held it in 17 quarters. The position peaked at $16.3M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Stifel Financial reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Stifel Financial sold 29,002 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $98K.
- Stifel Financial first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 17 quarters.
- Stifel Financial's Keryx Biopharmaceuticals Inc position peaked at $16.3M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Stifel Financial's 13F filing for Q4 2018, filed 13 Feb 2019.